〓疯子哥〓
第4楼2011/02/09
美国贝克曼库尔特有限公司开发和销售仪器,生化,软件以及能够简化和自动化实验室处理的产品。我们的产品能够支持在与疾病战斗的各个阶段的生物医学分析-从前沿医学研究到患者血液检测。在2004年,公司销售额为 $24亿,其中70%的销售额来自临床诊断市场,30%来自生物医学研究市场。稀释后每股收入(不包括特种费用/特别信贷)为$2.82。
贝克曼库尔特提供了一个广泛的分离,检测和分析生命组成部分的仪器业务。在医院临床实验室中,我们可以提供实际意义上的各种常规血液检测以及75%的其它检测。我们的70%以上的产品都保持在市场高端位置上:血液学,常规生化系统,离心,毛细管电泳,蛋白质分析,生物机器人以及快速检测。
我们系统的客户包括遍布全球的制药和生物技术公司,大学,医疗学院,研究机构,医院, 医师办公室,以及诊断实验室。贝克曼库尔特目前在全球范围内的实验室中拥有大约200,000主要的仪器系统,操作系统售后服务,生化试剂盒以及服务合同等代表了大约总收入的64%。
贝克曼重组于1988年, 在从SmithKline Beckman公司抽资脱离以后。在1998年,公司名称更改为美国贝克曼库尔特有限公司,反映出1997年与库尔特公司的并购关系。
丹纳赫公司(Danaher Corporation)成立于1984,是美国领先的制造商之一,也是一家年销售额超过80亿美元的快速成长的世界500强公司。在全球拥有37,000名员工。丹纳赫在专业仪器、工业技术以及工具和部件领域处于领先地位,并对知名且活跃的国际工业企业进行长期投资。
丹纳赫的产品旨在帮助全球人们生活得更健康、更安全、更舒心。其中某些产品品牌拥有很高知名度,另一些则在复杂的系统中默默工作。2004年,丹纳赫凭借有利的市场条件,实现了强劲的扩张、创记录的销量、收入以及现金流。
丹纳赫拥有获得成功所需的成熟系统:丹纳赫业务体系(DBS)。这一持续改进的体系不断推动着集团文化和业绩的全方位发展,指导和考量着集团日常活动。
丹纳赫拥有以下业务平台:
电子和测试业务:Fluke®,Fluke Networks® ,Raytek® 以及 BEHA® 电子及测试设备。
环境保护业务:Lang® ,Hach® ,Anatel® ,Pacific Scientific® ,Orbisphere® ,Veeder-Root® ,Gasboy® ,Gilbarco® ,以及Red-Jacket® 设备。
医疗技术业务:Gendex® 以及 Radiometer ™ 产品和服务。
运动控制业务:Dover ™,Kollmorgen® ,MEI® ,Pacific Scientific® ,Portescap ™ 和 Thomson® 运动控制产品和系统。
产品识别业务:Videojet® ,Willet® ,Accu-Sort® 产品和系统。
工具和部件业务:Armsrong® ,Matco® ,Sears Craftsman® ,Allen® ,KD-Tools ™ ,Holo-Krome® ,NAPA® ,和SATA® 手提工具及部件。
zwyu
第5楼2011/02/09
数据稍微有点旧,2005年左右的资料吧?
zwyu
第7楼2011/02/09
Danaher to Acquire Beckman Coulter, Inc. for $83.50 per share or $6.8 Billion
Washington, D.C., February 7, 2011 – Danaher Corporation (NYSE:DHR) announced today that it has entered into a definitive merger agreement with Beckman Coulter, Inc. (NYSE: BEC) pursuant to which Danaher will acquire Beckman Coulter by making a cash tender offer to acquire all of the outstanding shares of common stock of Beckman Coulter at a purchase price of $83.50 per share, for a total enterprise value of approximately $6.8 billion, including debt assumed and net of cash acquired.
The Beckman Coulter Board of Directors has unanimously recommended that Beckman Coulter shareholders accept and tender their shares into the offer, which represents a premium of approximately 45% to Beckman Coulter’s closing price on December 9, 2010, the date on which market speculation began regarding a potential sale of the Company. The offer is subject to customary conditions, including tender of a majority of the outstanding shares into the offer (on a fully diluted basis), applicable regulatory approvals and the absence of a material adverse change with respect to Beckman Coulter. The transaction is expected to be completed in the first half of 2011.
With annual revenues of approximately $3.7 billion, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Its diagnostic systems are found in hospitals and other clinical settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use its life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.
Beckman Coulter would become part of Danaher’s Life Sciences & Diagnostics segment, joining Danaher’s Leica, AB Sciex, Radiometer and Molecular Devices businesses.
Danaher’s President and CEO, H. Lawrence Culp, Jr., said, “Beckman Coulter is an iconic company with a great brand, broad reach and technology leadership; well positioned in the markets it serves. Beckman provides an excellent complement to our existing Life Sciences & Diagnostics businesses. Being part of Danaher, Beckman associates will have the opportunity to leverage the power of the Danaher Business System, including the processes by which Danaher accelerates growth through new product innovation and driving sales, marketing and service, as well as its strength in continuously expanding margins.”
zwyu
第8楼2011/02/09
http://www.danaher.com/business/directory.asp?currentLetter=all
丹纳赫旗下品牌,说有非法字符,发不上来,自己去看吧。